Business Report

Overview

The report describes Idorsia's 2021 progress from a research-focused biopharmaceutical company toward commercialization, including first product approvals in the US and Japan. It highlights an 11-asset pipeline, with six assets in late-stage development, and expansion into five European markets. The company also reported more than 1,100 employees and continued building its sustainability reporting through materiality assessment and planned GRI alignment.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services